Skip to main content
main-content

In depth

In depth

13-12-2017 | Biosimilars | Feature | Article

Biosimilars: The story so far

medwireNews provides an overview of the evidence supporting the equivalence of biosimilar drugs and their reference products, and answers some questions about the use of biosimilars in rheumatology.

10-10-2017 | Juvenile idiopathic arthritis | Feature | Article

Talking point: Are biologics over-used in the treatment of JIA?

Timothy Beukelman speaks to medwireNews about the differing viewpoints on whether biologic treatments are over-used for the treatment of children with juvenile idiopathic arthritis.

12-09-2017 | Rheumatoid arthritis | Feature | Article

At a glance: Trials evaluating baricitinib in RA

Our quick guide to the phase II and III trials of baricitinib for the treatment of rheumatoid arthritis. 

04-08-2017 | Rheumatoid arthritis | Feature | Article

At a glance: The ORAL trials of tofacitinib for the treatment of RA

Our quick-reference guide to the seven ORAL trials of tofacitinib for the treatment of rheumatoid arthritis that have been completed to date.

19-07-2017 | Rheumatoid arthritis | Feature | Article

JAK inhibitors for RA: Professor Roy Fleischmann speaks to medwireNews

Roy Fleischmann talks to medwireNews about the need for JAK inhibitors and their potential impact on the rheumatoid arthritis treatment landscape.

05-06-2017 | Rheumatoid arthritis | Feature | Article

JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis?

medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.

Ask the expert

Are you a healthcare professional with questions about the management of rheumatic disease? Submit a question here and we'll put a selection of the best to our Editorial Board.

Image Credits